Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Biogen banks on government coverage to restart stalled Alzheimer's drug sales

Stock MarketsOct 20, 2021 10:56AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S., March 9, 2020. REUTERS/Brian Snyder

By Manas Mishra and Dania Nadeem

(Reuters) -Biogen Inc is pinning its hopes on a decision on U.S. government coverage of its Alzheimer's disease drug next year to help drive up its usage, after a big miss on quarterly sales of the much-awaited treatment.

The company recorded $300,000 in sales of Aduhelm in the third quarter, compared with the $10.79 million mean estimate from 16 analysts, according to Refinitiv data.

Only 120 sites across the United States are offering the drug, Biogen (NASDAQ:BIIB) said, versus its expectations of 900 immediately after the launch. The company expects minimal sales from the treatment this year, while raising its forecasts on demand for its multiple sclerosis drugs.

Biogen is betting on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, to buffer a hit from its main revenue drivers facing rising competition.

However, the uptake has been slower than expected as several commercial insurers wait for further direction from Medicare before covering the drug, which is priced at $56,000 a year.

"We can't actually speculate on the outcome of the (review). But as you know, we do believe it will be a major milestone, and this will alleviate a lot of the confusion that we're seeing with physicians," Biogen U.S. President Alisha Alaimo told analysts on a post-earnings call.

Still, Wall Street's consensus expectations for 2022 sales of the drug are too high and should move lower, said Jefferies (NYSE:JEF) analyst Michael Yee. Aduhelm is expected to generate sales of $953 million next year, according to Refinitiv estimates.

Alaimo also said the price tag was not the main reason for hospitals refusing to use the drug so far, adding the company was offering financial assistance programs.

Meanwhile, Biogen raised its full-year adjusted earnings per share expectations to $18.85 to $19.35, from $17.50 to $19.00.

The company's shares were up 1.8% at $272.92 in early trading.

Biogen banks on government coverage to restart stalled Alzheimer's drug sales
 

Related Articles

American Airlines sees minor impact after 5G rollout
American Airlines sees minor impact after 5G rollout By Reuters - Jan 19, 2022

WASHINGTON (Reuters) - American Airlines (NASDAQ:AAL) said on Wednesday it had seen some delays and four cancellations as a result of new 5G service and some additional impact to...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
John Kelley
John Kelley Oct 20, 2021 7:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$14k per quarter cost per patient. $300k in revenue, so just over 20 patients. wow
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email